CLB-004 / ClostraBio - LARVOL DELTA

ClostraBio will present at the 14th Annual Biotech Showcase Event (PRWeb) - "ClostraBio, Inc. today announced that the company will be presenting a research and development update on its lead compound CLB-004 as well as the start of its Series A investment round at the Biotech Showcase™ 2022 conference from January 10-12 and 17-19...The company intends to use this data to raise a Series A investment round and advance CLB-004 into a Phase 1a/b clinical study in patients with mild-moderate ulcerative colitis. With an IND-enabling toxicology program underway, the company is currently planning a pre-IND interaction with FDA in the first half of 2022."

Financing • Inflammatory Bowel Disease • Ulcerative Colitis